Drug Search Results
More Filters [+]

Bevenopran

Alternative Names: bevenopran, cb-5945, cb5945, cb 5945, adl-5945, adl5945, adl 5945
Latest Update: 2018-11-15
Latest Update Note: Clinical Trial Update

Product Description

Bevenopran has been used in trials studying the treatment of Renal Impairment and Opioid-Induced Constipation. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Bevenopran)

Mechanisms of Action: OPRM Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bevenopran

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Constipation

Phase 1: Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

5945-SOIC-12-05

P3

Terminated

Constipation

2014-07-21

5945-OIC-12-04

P3

Terminated

Constipation

2014-02-13

5945-OIC-12-03

P3

Terminated

Constipation

2014-02-13

5945-OIC-12-02

P3

Terminated

Constipation

2014-02-13

Recent News Events

Date

Type

Title